Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β

21 Dec 2021

Abstract excerpt

Abstract Adoptive T cell therapy with T cells expressing affinity-enhanced TCRs has shown promising results in phase 1/2 clinical trials for solid and hematological tumors. However, depth and durability of responses to adoptive T cell therapy can suffer from an inhibitory tumor microenvironment. A common immune-suppressive agent is TGF-β, which is secreted by tumor cells and cells recruited to the tumor. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Research and Treatments
Share to CAR-T cell therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34853077
DOI: 10.4049/jimmunol.2001357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βPMID 34853077Read ↗

Generation of TGFβR2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapySemantic proximity Read ↗

Transforming growth factor‐β signaling: Tumorigenesis and targeting for cancer therapySemantic proximity Read ↗

CRISPR/Cas9-mediated TGFβRII Disruption Enhances Anti-tumor Efficacy of Human Chimeric Antigen Receptor T Cells in VitroSemantic proximity Read ↗

CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitroSemantic proximity Read ↗

Molecular Pathways: Targeting the TGF-β Pathway for Cancer TherapySemantic proximity Read ↗

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.Semantic proximity Read ↗

TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillanceSemantic proximity Read ↗

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.Semantic proximity Read ↗

Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapySemantic proximity Read ↗

Proactive and reactive roles of TGF-β in cancerSemantic proximity Read ↗

TGF Beta Inhibition for Cancer TherapySemantic proximity Read ↗

Blockade of TGF-β Signaling Greatly Enhances the Efficacy of TCR Gene Therapy of CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.